Background The MF59-adjuvanted trivalent inactivated influenza vaccine (aIIV3) is designed
to overcome immunosenescence and enhance vaccine responses in older adults. We …

Background Age-related immunosenescence may impair the immune response to
vaccination in older adults. Adjuvanted influenza vaccines are designed to overcome …

Background This study estimated the relative vaccine effectiveness (rVE) of the MF59-
adjuvanted trivalent influenza vaccine (aTIV) versus high-dose trivalent inactivated influenza …

Objectives This study evaluated relative vaccine effectiveness (rVE) of MF59-adjuvanted
trivalent inactivated influenza vaccine (aTIV) vs high-dose trivalent inactivated influenza …

Background Adults≥ 65 years of age have suboptimal influenza vaccination responses
compared to younger adults due to age‐related immunosenescence. Two vaccines were …

Traditional influenza vaccines may be less immunogenic in adults≥ 65 years of age due to
immunosenescence. Two influenza vaccines—MF59®-adjuvanted trivalent inactivated …

Background Vaccination is the best way to prevent influenza; however, greater benefits
could be achieved. To help guide research and policy agendas, we aimed to quantify the …

Traditional influenza vaccines may be less immunogenic in adults≥ 65 years of age due to
immunosenescence. Two influenza vaccines—MF59®-adjuvanted trivalent inactivated …

Background The effectiveness of standard, egg-derived quadrivalent influenza vaccines
(IIV4) may be reduced in adults≥ 65 years of age, largely because of immunosenescence …

Introduction The propensity for influenza viruses to mutate and recombine makes them both
a familiar threat and a prototype emerging infectious disease. Emerging evidence suggests …